Jeil, Takeda Korea to cooperate over new treatment of type 2 diabetes

Published: 2013-09-06 06:58:00

Updated: 2013-09-06 06:58:00

Jeil Pharm and Takeda Korea announced Wednesday that they have concluded an agreement to co-promote Nesina (alogliptin), Takeda’s new treatment for type 2 diabetes in adults as adjuncts to diet and exercise.

Nesina is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is designed to slow the inac...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK